Invitrogen news from FierceBiotech
NewsInvitrogen gets breast cancer test approval
Invitrogen has won FDA approval of a test that can determine whether a woman with breast cancer will benefit from Genentech's Herceptin. The SPOT-Light test, as it is known, uses a DNA probe for the Read more...
Invitrogen, Applera agree on $6.7B merger
Two big suppliers to the drug development business are merging. Invitrogen has agreed to acquire all of the shares of Applera's Read more...
Novartis established nonprofit vaccine institute
Novartis has established the Novartis Vaccines Institute for Global Health, a nonprofit venture that will take aim at diseases in the developing world. The NVGH, which will be separate from Novartis' Read more...
Invitrogen puts up $57M for CellzDirect buyout
Invitrogen is buying out CellzDirect in a $57 million cash deal. CellzDirect provides R&D operations hepatocyte-based cell products and other services used to test new drugs. Primary human Read more...
ALSO NOTED: VaxGen gains extension; Merck wins latest Vioxx suit;and much more...> Officials at HHS have granted VaxGen a one-month extension of its deadline to resolve a clinical hold on its troubled development program for an anthrax vaccine. The agency has threatened to cancel its contract with VaxGen unless it resolves the hold. Report > Biotech drugs take longer … Read more...C&L: Drakeman resigns from Medarex
Medarex CEO Donald Drakeman (photo) resigned his post as the company issued new findings in its investigation of how stock options were granted over the past 10 … Read more...ALSO NOTED: Curis discontinues partnership; Invitrogen buying Sentigen; and much more...> Curis announced that it is discontinuing a partnership with Genentech to co-develop a basal cell carcinoma candidate. They had already stopped a Phase I trial involved in the deal and had announced that they would not pursue a clinical evaluation of the therapy in that formulation. Report > … Read more...C&L: DeBone steps down from Mylan post
Louis J. DeBone, president and CEO for Mylan Laboratories, has announced plans to retire. Glades Pharmaceuticals has announced the appointment of Darren Alkins to the position of president. CoTherix has named Abhay Joshi, Ph.D. executive vice president and chief technical officer. Pharsight … Read more...ALSO NOTED: MicroIslet warns of cash shortage; Invitrogen, Signalomics in pact; and much more...> San Diego-based MicroIslet is warning investors it only has enough money to fund operations through June. Report > Invitrogen and Germany's Signalomics have inked a pact to collaborate on nanotech-based approaches to diagnosing cancer. Report > The FDA has granted … Read more...Cyclacel to go public in reverse merger with XcyteIn a reverse merger, Seattle-based Xcyte Therapies is taking over Scotland's Cyclacel Pharmaceuticals in a deal that will allow Cyclacel to emerge as a public company in the US. Xcyte shareholders will wind up with 20 percent of the new company, which will be based in Short Hills, NJ. Xcyte was reduced to a mere shell company earlier this year after the FDA raised objections to its design of a major clinical trial of technology designed to arouse the immune system to ward off disease. … Read more... | Press ReleasesPRESS RELEASE: Crucell Licenses Technology to Invitrogen Corporation Crucell Licenses Technology to Invitrogen Corporation Leiden, The Netherlands, September 6, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets